100 related articles for article (PubMed ID: 27113564)
1. DNA-PKcs Expression Is a Predictor of Biochemical Recurrence After Permanent Iodine 125 Interstitial Brachytherapy for Prostate Cancer.
Molina S; Guerif S; Garcia A; Debiais C; Irani J; Fromont G
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):965-972. PubMed ID: 27113564
[TBL] [Abstract][Full Text] [Related]
2. DNA-PKcs expression predicts response to radiotherapy in prostate cancer.
Bouchaert P; Guerif S; Debiais C; Irani J; Fromont G
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1179-85. PubMed ID: 22494583
[TBL] [Abstract][Full Text] [Related]
3. Is prostate-specific antigen percentage decrease predictive of clinical outcome after permanent iodine-125 interstitial brachytherapy for prostate cancer?
Paoluzzi M; Mignogna M; Lorenzini E; Valent F; Fontana N; Pinzi N; Repetti F; Ponchietti R
Brachytherapy; 2012; 11(4):277-83. PubMed ID: 22137870
[TBL] [Abstract][Full Text] [Related]
4. Primary Gleason grade 4 impact on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer.
Uesugi T; Saika T; Edamura K; Nose H; Kobuke M; Ebara S; Abarzua F; Katayama N; Yanai H; Nasu Y; Kumon H
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e219-23. PubMed ID: 21640517
[TBL] [Abstract][Full Text] [Related]
5. Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: The Memorial Sloan-Kettering Cancer Center experience.
Zelefsky MJ; Chou JF; Pei X; Yamada Y; Kollmeier M; Cox B; Zhang Z; Schechter M; Cohen GN; Zaider M
Brachytherapy; 2012; 11(4):245-9. PubMed ID: 21925957
[TBL] [Abstract][Full Text] [Related]
6. Quadrant dosimetry as a predictor of biochemical relapse in 125I prostate brachytherapy.
Spadinger I; Morris WJ; Keyes M; Liu M; Shaffer R; Thompson A; Chng N; Woods R
Brachytherapy; 2011; 10(2):87-97. PubMed ID: 20691643
[TBL] [Abstract][Full Text] [Related]
7. Expression of Ku70 predicts results of radiotherapy in prostate cancer.
Hasegawa T; Someya M; Hori M; Matsumoto Y; Nakata K; Nojima M; Kitagawa M; Tsuchiya T; Masumori N; Hasegawa T; Sakata KI
Strahlenther Onkol; 2017 Jan; 193(1):29-37. PubMed ID: 27465041
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of the Biochemical Recurrence risk between Radical Prostatectomy and Brachytherapy in the treatment of low- and intermediate-risk prostate cancer].
Martínez PF; Belisle DF; Cristallo C; Tobía I; Damia O; Villamil W; Giudice CR
Arch Esp Urol; 2015 Oct; 68(8):655-60. PubMed ID: 26437328
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?
Papagikos MA; Deguzman AF; Rossi PJ; McCullough DL; Clark PE; Lee WR
Brachytherapy; 2005; 4(4):252-8. PubMed ID: 16344254
[TBL] [Abstract][Full Text] [Related]
10. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
11. Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK.
Dickinson PD; Malik J; Mandall P; Swindell R; Bottomley D; Hoskin P; Logue JP; Wylie JP
BJU Int; 2014 May; 113(5):748-53. PubMed ID: 24053230
[TBL] [Abstract][Full Text] [Related]
12. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
[TBL] [Abstract][Full Text] [Related]
13. PSA bounce after ¹²⁵I-brachytherapy for prostate cancer as a favorable prognosticator.
Engeler DS; Schwab C; Thöni AF; Hochreiter W; Prikler L; Suter S; Stucki P; Schiefer J; Plasswilm L; Schmid HP; Putora PM
Strahlenther Onkol; 2015 Oct; 191(10):787-91. PubMed ID: 26100965
[TBL] [Abstract][Full Text] [Related]
14. Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?
Galego P; Silva FC; Pinheiro LC
Int Braz J Urol; 2015; 41(2):353-9. PubMed ID: 26005979
[TBL] [Abstract][Full Text] [Related]
15. DNA ploidy measured on archived pretreatment biopsy material may correlate with prostate-specific antigen recurrence after prostate brachytherapy.
Keyes M; Macaulay C; Hayes M; Korbelik J; Morris WJ; Palcic B
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):829-34. PubMed ID: 23688814
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the impact of isotope ((125)I vs. (103)Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer.
Kollmeier MA; Pei X; Algur E; Yamada Y; Cox BW; Cohen GN; Zaider M; Zelefsky MJ
Brachytherapy; 2012; 11(4):271-6. PubMed ID: 22192495
[TBL] [Abstract][Full Text] [Related]
17. Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M. D. Anderson Cancer Center experience with (125)iodine brachytherapy.
Frank SJ; Levy LB; Kuban DA; Lee AK; Kudchadker RJ; Bruno TL; van Vulpen M; Swanson DA
J Urol; 2009 Apr; 181(4):1658-63; discussion 1663-4. PubMed ID: 19233434
[TBL] [Abstract][Full Text] [Related]
18. [Outcomes and predictors of T3a prostate cancer treated by permanent interstitial brachytherapy combined with external radiotherapy and hormone therapy].
Mai Z; Yan W; Li H; Zhou Y; Zhou Z; Chen J
Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):765-70. PubMed ID: 25573217
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone.
Rossi PJ; Urbanic J; Clark PE; McCullough DL; Lee WR
Brachytherapy; 2008; 7(4):286-9. PubMed ID: 18928924
[TBL] [Abstract][Full Text] [Related]
20. DNA-PKcs and Ku70 are predictive markers for poor prognosis of patients with gall bladder malignancies.
Ren F; Yang ZL; Tan X; Liu D; Zou Q; Yuan Y; Li J; Liang L; Zeng G; Chen S
Appl Immunohistochem Mol Morphol; 2014; 22(10):741-7. PubMed ID: 25046228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
